Asia-Pacific Oncology Molecular Diagnostics Market by Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer & Others), End User (Hospitals, Reference Laboratories, & Others), Country (Australia, Vietnam, Thailand, Philippines & Rest of Asia-Pacific): Regional Opportunity Analysis and Industry Forecast, 20192026
- Published Date: 2020-11-18
- Report ID: 18217
- Pages: 158
-
Format:
The Asia Pacific oncology molecular diagnostics market was valued at $381.84 million in 2018 and is projected to reach $732.05 million by 2026, registering a CAGR of 9.0% from 2019 to 2026.
Molecular diagnostics is a set of cumulative techniques used for analyzing biological markers at molecular level such as genome and proteome. It is used for diagnosis and prediction of various infectious diseases, cancers, and other genetic disorders. Advancements in molecular diagnostics, including increased precision, faster turnarounds, and reduced costs act as key drivers for better genetic information.
The market is segmented on the basis of application, end user, and country. By application, it is categorized into lung, colorectal, breast, hematological, and others. By end user, it is segmented into hospitals, reference laboratories, and others (research institutes and academics). The hospitals segment was the highest contributor to the market, with $184.27 million in 2018, and is estimated to reach $354.46 million by 2026, at a CAGR of 9.0% during the forecast period.
Country wise, the market is divided into Australia, Vietnam, the Philippines, Thailand, and rest of Asia-Pacific. The oncology molecular diagnostics market growth, by country, is attributed to higher adoption and acceptance of personalized medicine, upgradation of healthcare infrastructure, and higher investments for R&D. Further, the market growth is attributed to increase in number of patients suffering from cancer in Asia-Pacific.
The key players profiled in this report include F. Hoffmann-La Roche AG, BioMrieux SA, Abbott Laboratories, Qiagen N.V., Sysmex, Danaher Corporation, S.A., Danaher, and Siemens Healthcare GmbH.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the Asia-Pacific oncology molecular diagnostics market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
KEY MARKET SEGMENTS
By Application
Breast cancer
o By Technology
PCR
By Type
o Instruments
o Reagents
o Software & Services
NGS
By Type
o Instruments
o Reagents
o Software & Services
Flow Cytometry
By Type
o Instruments
o Reagents
o Software & Services
FISH
By Type
o Instruments
o Reagents
o Software & Services
CISH
By Type
o Instruments
o Reagents
o Software & Services
o
Others
By Type
o Instruments
o Reagents
o Software & Services
Lung cancer
o By Technology
PCR
By Type
o Instruments
o Reagents
o Software & Services
NGS
By Type
o Instruments
o Reagents
o Software & Services
Flow Cytometry
By Type
o Instruments
o Reagents
o Software & Services
FISH
By Type
o Instruments
o Reagents
o Software & Services
CISH
By Type
o Instruments
o Reagents
o Software & Services
Others
By Type
o Instruments
o Reagents
o Software & Services
Colorectal cancer
o By Technology
PCR
By Type
o Instruments
o Reagents
o Software & Services
NGS
By Type
o Instruments
o Reagents
o Software & Services
Flow Cytometry
By Type
o Instruments
o Reagents
o Software & Services
FISH
By Type
o Instruments
o Reagents
o Software & Services
CISH
By Type
o Instruments
o Reagents
o Software & Services
Others
By Type
o Instruments
o Reagents
o Software & Services
Hematological cancer
o By Technology
PCR
By Type
o Instruments
o Reagents
o Software & Services
NGS
By Type
o Instruments
o Reagents
o Software & Services
Flow Cytometry
By Type
o Instruments
o Reagents
o Software & Services
FISH
By Type
o Instruments
o Reagents
o Software & Services
CISH
By Type
o Instruments
o Reagents
o Software & Services
Others
By Type
o Instruments
o Reagents
o Software & Services
Others
o By Technology
PCR
By Type
o Instruments
o Reagents
o Software & Services
NGS
By Type
o Instruments
o Reagents
o Software & Services
Flow Cytometry
By Type
o Instruments
o Reagents
o Software & Services
FISH
By Type
o Instruments
o Reagents
o Software & Services
CISH
By Type
o Instruments
o Reagents
o Software & Services
Others
By Type
o Instruments
o Reagents
o Software & Services
By End user
Hospitals
Reference Laboratories
Others
By Country
Australia
Thailand
The Philippines
Vietnam
Rest of Asia-Pacific
KEY MARKET PLAYERS
F. Hoffmann-La Roche AG
BioMrieux SA
Abbott Laboratories
Qiagen N.V.
Sysmex Corporation
Danaher Corporation, S.A.
Siemens Healthcare GmbH.
DiaSorin
Illumina
Agilent Technologies
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Key findings
3.1.1.Top Investment Pockets
3.1.2.Top Player Positioning, 2018
3.1.3.Key forces shaping the Asia-Pacific oncology molecular diagnostics market
3.2.Market dynamics
3.2.1.Drivers
3.2.1.1.Rise in prevalence of various types of cancersW
3.2.1.2.Growth in funding by governmentsW
3.2.1.3.Growth in biomarker identification
3.2.2.Restraints
3.2.2.1.Lack of skilled professionals
3.2.2.2.Stringent regulatory requirements for product approvals
3.2.3.Opportunities
3.2.3.1.Advancements in genomics and proteomics
3.3.Regulatory guidelines for molecular diagnostics
3.4.Recommended guidelines for oncology molecular diagnostics tests
3.5.Insights on clinical flow cytometry panel
3.6.Pricing ranges for technology
CHAPTER 4:ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION
4.1.Overview
4.1.1.Asia-Pacific oncology molecular diagnostics market, by application
4.2.Colorectal cancer
4.2.1.Asia-Pacific oncology molecular diagnostics market, by technology for colorectal cancer
4.2.2.Colorectal oncology molecular diagnostics market, by PCR-based technology
4.2.3.Colorectal oncology molecular diagnostics market, by NGS based technology
4.2.4.Colorectal oncology molecular diagnostics market, by flow cytometry based technology
4.2.5.Colorectal oncology molecular diagnostics market, by FISH based technology
4.2.6.Colorectal oncology molecular diagnostics market, by CISH based technology
4.2.7.Colorectal oncology molecular diagnostics market, by others based technology
4.3.Hematological cancer
4.3.1.Market size and forecast
4.3.2.Hematological oncology molecular diagnostics market, by PCR-based technology
4.3.3.Hematological oncology molecular diagnostics market, by NGS based technology
4.3.4.Hematological oncology molecular diagnostics market, by flow cytometry based technology
4.3.5.Hematological oncology molecular diagnostics market, by FISH based technology
4.3.6.Hematological oncology molecular diagnostics market, by CISH based technology
4.3.7.Hematological oncology molecular diagnostics market, by others based technology
4.4.Breast cancer
4.4.1.Market size and forecast
4.4.2.Breast oncology molecular diagnostics market, by PCR-based technology
4.4.3.Breast oncology molecular diagnostics market, by NGS based technology
4.4.4.Breast oncology molecular diagnostics market, by flow cytometry based technology
4.4.5.Breast oncology molecular diagnostics market, by FISH based technology
4.4.6.Breast oncology molecular diagnostics market, by CISH based technology
4.4.7.Breast oncology molecular diagnostics market, by others based technology
4.5.Lung cancer
4.5.1.Market size and forecast
4.5.2.Lung oncology molecular diagnostics market, by PCR-based technology
4.5.3.Lung oncology molecular diagnostics market, by NGS based technology
4.5.4.Lung oncology molecular diagnostics market, by flow cytometry based technology
4.5.5.Lung oncology molecular diagnostics market, by FISH based technology
4.5.6.Lung oncology molecular diagnostics market, by CISH based technology
4.5.7.Lung oncology molecular diagnostics market, by others based technology
4.6.Other cancers
4.6.1.Market size and forecast
4.6.2.Others oncology molecular diagnostics market, by PCR-based technology
4.6.3.Others oncology molecular diagnostics market, by NGS based technology
4.6.4.Others oncology molecular diagnostics market, by flow cytometry based technology
4.6.5.Others oncology molecular diagnostics market, by FISH based technology
4.6.6.Others oncology molecular diagnostics market, by CISH based technology
4.6.7.Others oncology molecular diagnostics market, by others based technology
CHAPTER 5:ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY END USER
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospitals
5.2.1.Market size and forecast
5.3.Reference laboratories
5.3.1.Market size and forecast
5.4.Others
5.4.1.Market size and forecast
CHAPTER 6:ASIA-PACIFIC ONCOLOGY MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY
6.1.Overview
6.1.1.Key market trends and opportunities
6.1.2.Asia-Pacific Oncology Molecular Diagnostics market, by country
6.2.Australia
6.2.1.Australia oncology molecular diagnostics market, by application
6.2.2.Australia oncology molecular diagnostics market, by end user
6.2.3.Market share analysis of top players, 2018
6.3.Vietnam
6.3.1.Vietnam oncology molecular diagnostics market, by application
6.3.2.Vietnam oncology molecular diagnostics market, by end user
6.3.3.Market share analysis of top players, 2018
6.4.Thailand
6.4.1.Thailand oncology molecular diagnostics market, by application
6.4.2.Thailand oncology molecular diagnostics market, by end user
6.4.3.Market share analysis of top players, 2018
6.5.Philippines
6.5.1.Philippines oncology molecular diagnostics market, by application
6.5.2.Philippines oncology molecular diagnostics market, by end user
6.5.3.Market share analysis of top players, 2018
6.6.Rest of Asia-Pacific
6.6.1.Rest of Asia-Pacific oncology molecular diagnostics market, by application
6.6.2.Rest of Asia-Pacific oncology molecular diagnostics market, by end user
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.bioMrieux SA
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Product portfolio
7.2.4.Business performance
7.2.5.Key strategic moves and developments
7.3.Qiagen N.V.
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments
7.4.F. Hoffmann-La Roche Ltd
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.Siemens Healthineers
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.6.Danaher (Cepheid)
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.Diasorin SPA
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Product portfolio
7.7.4.Business performance
7.7.5.Key strategic moves and developments
7.8.Illumina Inc.
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.Agilent Technologies Inc.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.Sysmex Corporation
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
